Clinical efficacy and safety of antiobesity agents

Keyphrases

• Clinical Efficacy 100%
• Clinical Safety 100%
• Anti-obesity 100%
• Anorexiant 100%
• Weight Loss 66%
• Lipase Inhibitor 66%
• Obesity 33%
• Leptin 33%
• Obesity Treatment 33%
• Mechanism of Action 33%
• FDA-approved Drugs 33%
• Comorbid Conditions 33%
• Medication Use 33%
• New Advances 33%
• Related Conditions 33%
• Thermogenic 33%
• Lifestyle Modification 33%
• Lose Weight 33%
• Drug Class 33%
• Weight Management 33%
• Long-term Health Outcomes 33%
• Effective Weight 33%
• Peptide Analogs 33%
• Managed Care Organization 33%
• Serotonergic Activity 33%
• Formulary 33%
• Physician Office 33%
• Fenfluramine 33%
• Orlistat 33%
• Sibutramine 33%
• Short-term Use 33%
• Adrenoceptor Agonist 33%
• Adrenergic Activity 33%
• Tetrahydrolipstatin 33%
• β3-adrenoceptor 33%

Medicine and Dentistry

• Drug Therapy 100%
• Antiobesity Drugs 100%
• Anorexigenic Agent 75%
• Orlistat 50%
• Lipase Inhibitors 50%
• Side Effect 25%
• Health Outcomes 25%
• Lifestyle Modification 25%
• Adrenergic Activity 25%
• Weight Management 25%
• Fenfluramine 25%
• Sibutramine 25%
• Beta 3 Adrenergic Receptor Stimulating Agent 25%
• Leptin 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Anorexigenic Agent 100%
• Antiobesity Drugs 100%
• Tetrahydrolipstatin 66%
• Esterase Inhibitor 66%
• Side Effect 33%
• Sibutramine 33%
• Beta 3 Adrenergic Receptor Stimulating Agent 33%
• Leptin 33%
• Fenfluramine 33%